Grants8

Grant Information	Key Details	Eligibility & Funding
Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional) PAR-25-227 Programme: National Institutes of Health (NIH)	Core objective: Expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs to facilitate appropriate interventions. Target recipient type and size: A broad range of organizations including Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), Local and Federal Governments, and other entities. There is no specified organizational size limit. SECTOR-SPECIFIC: This grant is primarily focused on the Healthcare/Medical Research, Public Health, Child Health, Genetics, and Rare Diseases sectors. Geographic scope: Organizations from the United States and non-U.S. (Foreign Organizations) are eligible to apply. Key filtering criteria for initial grant screening: Applicants must focus on disorders related to newborn screening and propose research that addresses specific goals such as identifying underlying biological mechanisms, improving diagnostic accuracy, facilitating clinical trials, or establishing data collection systems. Grant frequency and program context: This is a recurring funding opportunity with multiple application cycles per year until October 2027. It is a reissue of PAR-21-115 and is part of the Hunter Kelly Newborn Screening Research Program within NICHD, aligning with recommendations from the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) and the Recommended Uniform Screening Panel (RUSP).	Funding Up to None USD Deadline Oct. 5, 2027, 5 p.m.	Details
Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional) PAR-25-265 Programme: National Institutes of Health (NIH)	The core objective of this R01 grant is to encourage research that develops novel screening approaches and/or therapeutic interventions for screenable disorders in newborns. This includes conditions already part of newborn screening panels and potentially fatal or disabling genetic conditions that could benefit from early detection. - Target recipients: A wide range of organizations including Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), various levels of Government (Local, State, Federal, Tribal), Independent School Districts, Public Housing Authorities, Tribal Organizations, Faith-based/Community-based Organizations, Regional Organizations, and Foreign Organizations. - Organizational size: Not explicitly limited, open to organizations of various capacities capable of conducting research. - Designation: SECTOR-SPECIFIC (Healthcare/Biomedical Research). - Geographic scope: Eligible organizations from the United States and non-U.S. entities (foreign organizations) are welcome to apply. - Key filtering criteria: Projects must focus on research related to newborn screening technologies, assays, or therapeutic interventions for genetic and congenital disorders in infants. - Grant frequency: This is a recurring grant opportunity with multiple application due dates until its expiration in November 2027, reissuing a previous program.	Funding Up to None USD Deadline Nov. 5, 2027, 9 p.m.	Details
Genomic Community Resources (U24 Clinical Trial Not Allowed) PAR-23-124 Programme: National Institutes of Health (NIH)	Single, clear statement of grant's core objective: To facilitate genomic research by supporting the development and distribution of high-value genomic resources for broad use by the research community. Explicit identification of target recipient type and size: Open to a wide range of organization types including higher education, non-profits, for-profits (including small businesses), and various government entities. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC Geographic scope and any location requirements: Global eligibility, open to U.S. and non-U.S. entities (Foreign Institutions). Key filtering criteria for initial grant screening: Project must focus on creating or maintaining broadly applicable genomic resources (e.g., analysis tools, data standards, data production, sample collections). Projects supporting only specific diseases or biological questions are not appropriate. Clinical trials are not allowed. Must demonstrate broad community need and utility. Grant frequency and program context: Recurring funding opportunity with multiple application due dates until January 2026. Part of the National Institutes of Health (NIH) grant programs, specifically a cooperative agreement (U24) involving substantial federal programmatic involvement.	Funding Up to None USD Deadline Jan. 25, 2026, 10 p.m.	Details
Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional) PAR-25-327 Programme: National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) Ultra-Rare Gene-Based Therapy (URGenT) network	The core objective of this grant is to accelerate the development of gene-based or transcript-directed therapeutic candidates for ultra-rare neurological and neuromuscular disorders. It specifically supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing. Target Recipient Type: A wide range of organizations including higher education institutions, nonprofits, for-profit organizations (small and large businesses), various government entities, and other specified organizations. Target Recipient Size: Not explicitly limited by employee count or revenue, open to various organizational sizes with the capacity to conduct complex research. Designation: SECTOR-SPECIFIC (biomedical research, neuroscience, gene therapy). Geographic Scope: United States-based organizations. Foreign entities are not eligible to apply, but foreign components within U.S. organizations are allowed. Key Filtering Criteria: Focus on ultra-rare neurological and neuromuscular disorders (affecting <= 6,000 people in the U.S.). Proposed intervention must be a gene-based or transcript-directed therapeutic. Projects must be ready to undertake IND-enabling studies and clinical trial planning. Applicants must demonstrate robust proof of concept (POC) data for their therapeutic candidate. Must have scheduled or held pre-IND discussions with the FDA. Grant Frequency and Program Context: This is a reissue (PAR-25-327) of a previous funding opportunity (PAR-22-030), indicating a recurring nature. It is part of the National Institute of Neurological Disorders and Stroke (NINDS) Ultra-Rare Gene-based Therapy (URGenT) network.	Funding Up to None USD Deadline Oct. 8, 2027, 5 p.m.	Details
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) PA-20-272 Programme: National Institutes of Health (NIH)	Core objective: Provide administrative supplements to existing NIH research grants and cooperative agreements to cover increased, unforeseen costs within the approved scope. Target recipient: Program Directors/Principal Investigators (PDs/PIs) holding specific types of NIH research grants. Size: Not limited by organizational size; applies to various research entities holding NIH grants. SECTOR-SPECIFIC: Health and Biomedical Research, defined by the missions of participating NIH Institutes/Centers. Geographic scope: Predominantly United States, implicitly covers institutions eligible for NIH funding. Key filtering criteria: Applicant must already hold an existing, eligible NIH research grant or cooperative agreement. Grant frequency: Recurring, as evidenced by its status as a reissue (PA-20-272 reissues PA-18-591), indicating an ongoing program.	Funding Up to None USD Deadline Sept. 30, 2025, midnight	Details
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) PAR-25-332 Programme: National Institutes of Health (NIH)	This grant aims to fund research projects focused on current topics in Alzheimer's Disease (AD) and its related dementias (ADRD). It encourages biomedical, social, and behavioral research and training to better understand aging processes and related diseases. Core Objective: To invite applications for research on current topics in Alzheimer's disease and its related dementias (ADRD). Target Recipient Type and Size: Open to a wide range of organizations including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities (local, state, federal, tribal). There are no explicit size restrictions, allowing for a broad range of organizational scales. SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC for health and medical research, particularly neuroscience and aging studies. Geographic Scope: Worldwide, as non-domestic (non-U.S.) entities are eligible to apply. Key Filtering Criteria: Focus on AD/ADRD research, organizational type (must be one of the listed categories), and ability to meet extensive federal compliance and reporting requirements. Grant Frequency and Context: This is a recurring opportunity, a reissue of a previous Notice of Funding Opportunity (NOFO) PAR-22-093, indicating an ongoing commitment to this research area. It is developed in response to recommendations from AD/ADRD Research Summits and the National Alzheimer's Project Act (NAPA).	Funding Up to None USD Deadline Oct. 5, 2027, 10 p.m.	Details
Prospective Research PRB Programme: Prospective Research Program	– Core objective: To fund academic research projects that generate new knowledge on societal problems impacting the Brussels-Capital Region, with the goal of informing public policy and political debate by exploring alternatives to existing systems. – Target recipient: Primarily research institutions, including universities, research institutes, and other research-oriented entities. – Type/Size: Targets research institutions of varying sizes, as defined by their primary objective of conducting independent research and disseminating results. – SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC, focusing on societal challenges, strategic innovation domains, and regional competencies relevant to the Brussels-Capital Region. – Geographic scope: Brussels-Capital Region, Belgium. – Key filtering criteria: Academic research focus, direct relevance to the Brussels-Capital Region's urban challenges, contribution to public policy and debate, and an approach that explores possibilities and alternatives. – Grant frequency and program context: This is a recurring grant program, with a new edition launched annually.	Funding Up to None EUR Deadline Oct. 15, 2025, 9:59 p.m.	Details
Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional) PAR-25-050 Programme: National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS)	GRANT PURPOSE AND TARGET: - Support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. - Explicit identification of target recipient type and size: The grant targets a wide range of U.S.-based organizations, including higher education institutions, nonprofits, for-profit businesses (small and other), and various government entities. There are no explicit size restrictions, but applicants must have the capacity and expertise for complex research. - SECTOR-SPECIFIC: Healthcare (Neurology, Neuromuscular Disorders) and Technology (Biomarker Analytical Methods). - Geographic scope: Organizations must be based in the United States. Foreign components are allowed within a U.S. application, but foreign entities cannot be the primary applicant. - Key filtering criteria: Focus on analytical validation of biomarkers, not early discovery or clinical efficacy trials. Must address neurological or neuromuscular disorders. Must have preliminary data supporting biomarker utility and a developed detection method. Must specify context(s) of use and include milestones. - Grant frequency and program context: This is a reissue of PAR-24-095, indicating a recurring funding opportunity within the National Institute of Neurological Disorders and Stroke (NINDS) program to advance biomarker development for clinical readiness.	Funding Up to None USD Deadline June 22, 2026, 5 p.m.	Details
Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed) PAR-23-248 Programme: National Institutes of Health (NIH)	SECTOR-SPECIFIC: This grant aims to cultivate a highly integrated cohort of pre-doctoral and post-doctoral trainees and early career investigators, and to develop career development resources to accelerate kidney, urologic, and hematologic research. It targets higher education institutions, nonprofits, and government entities capable of establishing large-scale, interdisciplinary training programs. Geographic Scope: Primarily US-based institutions. Non-domestic entities are not eligible to apply. Key filtering criteria: Focus on kidney, urologic, and hematologic research training, cooperative agreement (U2C-TL1) mechanism, clinical trial not allowed for the overall program, but clinical trial experience for trainees is permitted. Grant Frequency: Recurring, with multiple application due dates until September 2025, reissued from a previous program.	Funding Up to None USD Deadline Sept. 26, 2025, 9 p.m.	Details
Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35) PA-25-280 Programme: Ruth L. Kirschstein National Research Service Award (NRSA)	This grant aims to develop and/or enhance short-term research training opportunities for predoctoral students in biomedical, behavioral, or clinical research. Target recipients are eligible, domestic institutions, primarily higher education institutions and non-profits, with a focus on supporting health professional students (medical, veterinary, other health-professional programs) and graduate students in physical or quantitative sciences. This is a SECTOR-SPECIFIC grant, focused on biomedical, behavioral, and clinical research training within health sciences. Geographic scope is limited to domestic (U.S.) institutions. Foreign organizations or non-U.S. components of U.S. organizations are not eligible. Key filtering criteria: Applicant must be a U.S. institution with established research training programs capable of supporting predoctoral students for short-term, intensive research experiences (8-12 weeks). This is a recurring grant opportunity, a reissue of PA-23-080, indicating a continuous program.	Funding Up to None USD Deadline Jan. 25, 2028, 5 p.m.	Details
Kozminski Impact Booster Kozminski Impact Booster Programme: Fundusze Europejskie dla Nowoczesnej Gospodarki	This grant aims to provide financial support, mentoring, and technological expert assistance to innovative startups and micro/small enterprises. The core objective is to develop competitive advantages and market maturity, enabling long-term, dynamic growth based on stable market, competence, and capital foundations. - Explicit identification of target recipient type and size: Startups, micro and small enterprises (MŚP). - Primarily SECTOR-SPECIFIC focusing on innovations within National Smart Specializations (such as IT, communication, geoinformation, automation, robotics, sustainable energy), but also includes a SECTOR-AGNOSTIC path for product development. - Geographic scope: Project implementation must be in Poland, with territorial reach extending to Poland and internationally. - Key filtering criteria for initial grant screening: Must be an innovative micro or small enterprise, less than 5 years old from registration, not listed on the stock exchange, and compliant with 'de minimis' aid conditions. - Grant frequency: The accelerator program was planned to execute 5 rounds; however, the current call is stated as 'closed'.	Funding Up to None PLN Deadline June 30, 2026, 11:59 p.m.	Details
NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) PAR-23-242 Programme: National Institutes of Health (NIH)	This grant, the NCI Research Specialist Award (R50), aims to establish and support stable research career opportunities for exceptional, non-tenure track laboratory-based scientists working within existing NCI-funded cancer research programs. It provides salary and limited travel support to these vital scientists, enabling them to pursue research without sole dependence on grants held by others. - Target Recipient Type: Academic and research institutions applying on behalf of highly skilled, non-tenure track scientists. - Target Recipient Size: SECTOR-AGNOSTIC regarding organizational size, as it supports individuals within various institutional settings (universities, nonprofits, for-profits, government). - Geographic Scope: United States-based organizations; foreign institutions are not eligible. - Key Filtering Criteria: Applicant organization must be US-based; the individual scientist (PD/PI) must be a non-tenure track, lab-based scientist with an advanced degree, significant experience in NCI-funded cancer research, and currently supported by an NCI-funded Unit Director. - Grant Frequency: Recurring, with annual application due dates (November 2023, 2024, 2025).	Funding Up to None USD Deadline Nov. 3, 2025, 5 p.m.	Details
LIFE Programme: EU Funding for Environment and Climate Action LIFE Programme: LIFE Programme	To contribute to a better European nature, environment, and climate policy. - Funding for innovative projects that protect the environment, save resources, conserve nature and biodiversity, and raise awareness. - Target recipients: Businesses (SMEs, large enterprises, startups), research institutions, governments, NGOs, and other organizations. - Size: All sizes of organizations. - SECTOR-SPECIFIC: Focuses on environmental, climate, and clean energy sectors. - Geographic Scope: Primarily EU Member States, but activities outside the EU can be funded if they benefit EU environmental/climate goals. - Frequency: Annual calls.	Funding Up to None EUR Deadline Sept. 23, 2025, 10:59 p.m.	Details
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) PAR-24-293 Programme: Blueprint Neurotherapeutics Network	This grant aims to accelerate the discovery and development of diverse biotherapeutic modalities for treating nervous and neuromuscular system disorders. - It supports projects from lead optimization through first-in-human clinical trials. - Target recipients are research teams led by Program Directors/Principal Investigators (PD/PIs) from various eligible organizations. - This grant is SECTOR-SPECIFIC. - Geographic scope includes both domestic (U.S.) and non-domestic (non-U.S.) entities. - Key filtering criteria: focus on biologics, nervous/neuromuscular system disorders, lead optimization to FIH clinical trial stage. - Grant frequency: Recurring, as a re-issue of a previous funding opportunity (PAR-21-163). - Program context: Part of NIH's Blueprint for Neuroscience Research, bridging the gap in biotherapeutics development by providing funding and in-kind resources like Contract Research Organizations (CROs) and consultants.	Funding Up to None null Deadline July 15, 2027, 5 p.m.	Details
Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required) PAR-25-098 Programme: National Institutes of Health (NIH) - ADVANCE Initiative	To test interventions that expand cancer screening and preventive services in NIH-designated health disparity populations by addressing barriers and facilitators at multiple socio-ecological levels. - Explicit identification of target recipient type and size: Primarily research institutions, non-profits, and government entities of various sizes capable of conducting clinical trials. - SECTOR-SPECIFIC - Geographic scope and any location requirements: United States, including U.S. Territories and Possessions. Non-U.S. entities are ineligible. - Key filtering criteria for initial grant screening: Must be a clinical trial, focus on cancer screening/prevention, target health disparity populations, and address multi-level barriers. - Grant frequency and program context: Recurring opportunity (multiple deadlines annually) as part of the NIH's ADVANCE initiative to increase randomized intervention research in health disparities.	Funding Up to None USD Deadline Jan. 7, 2027, 5 p.m.	Details
Translational Neural Devices (R61/R33 - Clinical Trial Optional) PAR-25-053 Programme: National Institutes of Health (NIH)	Core objective: Advance low-risk therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems by supporting translational activities and small clinical studies. Explicit identification of target recipient type and size: The grant targets investigators across a broad range of organization types, including academic institutions, non-profits, for-profit businesses (small and large), and various government entities. SECTOR-SPECIFIC: Healthcare (Medical Devices - Neurology/Neuromuscular). Geographic scope and any location requirements: Open to organizations within the United States and Non-domestic (non-U.S.) Entities (Foreign Organizations). Key filtering criteria for initial grant screening: Must focus on low-risk therapeutic or diagnostic neural devices for a single neurological or neuromuscular disorder, follow a two-phase (R61/R33) development model (non-clinical testing leading to a small clinical study), and exclude high-risk clinical trials or basic research. Grant frequency and program context: This is a recurring funding opportunity, noted as a reissue of PAR-24-151.	Funding Up to None USD Deadline Jan. 28, 2027, 5 p.m.	Details
Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required) PA-24-190 Programme: National Institutes of Health (NIH) Research Career Development Program	The core objective of this grant is to attract productive professionals with quantitative science and engineering backgrounds (e.g., mathematics, statistics, computer science, physics) to NIH-relevant biomedical, behavioral, bioimaging, or bioengineering research. It specifically targets individual investigators who propose to serve as the lead researcher for an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial. This is a SECTOR-SPECIFIC grant, focused on health and biomedical research. Geographic scope requires the applicant organization to be U.S.-based. However, foreign components and international sites are permitted for the actual conduct of clinical trials. Key filtering criteria: Individuals must possess an advanced quantitative degree, intend to lead an independent clinical trial, and secure strong institutional and mentorship support within NIH's mission areas. This is a recurring grant opportunity, part of the broader NIH Research Career Development program.	Funding Up to None USD Deadline Feb. 12, 2027, 5 p.m.	Details
Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Not Allowed) PA-24-185 Programme: NIH Research Career Development Program	The Mentored Patient-Oriented Research Career Development Award (K23) aims to support the career development of individuals with clinical doctoral degrees who are committed to patient-oriented research. It provides salary and research support for 3-5 years of 'protected time' to help these individuals become independent investigators. - Target recipient type: Individuals with clinical doctoral degrees focused on patient-oriented research. - Target recipient size: Individual researchers; associated with organizations of various sizes. - SECTOR-SPECIFIC - Geographic scope: United States organizations only (foreign components of U.S. organizations are allowed, but foreign organizations are not eligible). - Key filtering criteria: Applicant must hold a clinical doctoral degree and commit to patient-oriented research; research must NOT involve leading an independent clinical trial. - Grant frequency: Recurring (Parent NOFO with multiple application due dates until May 2027). - Program context: Part of NIH's broader Research Career Development program to ensure a pool of highly trained scientists in biomedical, behavioral, and clinical research.	Funding Up to None USD Deadline May 8, 2027, 10 p.m.	Details
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed) PAR-25-243 Programme: National Institutes of Health (NIH)	This grant aims to support basic, mechanistic research into the biological and genetic causes of cancer health disparities. It seeks to fund innovative studies that investigate these biological/genetic contributors, develop new methodologies and models, and utilize secondary data analyses. Target recipients: Investigators and scientists with expertise in basic research related to cancer health disparities. SECTOR-SPECIFIC: Healthcare, specifically cancer research. Geographic scope: Nationwide (US) and international (Non-U.S. Entities are eligible to apply). Key filtering criteria: Focus on basic mechanistic research, exclude clinical trials, must address cancer health disparities tied to race/ethnicity. Grant frequency: Recurring, with multiple application deadlines through October 2027. This is a reissue of a previous funding opportunity (PAR-24-277).	Funding Up to None USD Deadline Nov. 5, 2027, 10 p.m.	Details
Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) PAR-23-148 Programme: National Institutes of Health (NIH) Funding	Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) aims to support epidemiological and observational research on the long-term cardiopulmonary effects after tuberculosis (TB) treatment, particularly focusing on individuals with and without HIV infection. Primary objective: Characterize and understand adverse outcomes and morbidity associated with post-TB lung disease (PTLD) through additional testing and data collection in existing cohorts. Target recipients: Researchers and institutions (academic, non-profit, for-profit, government entities). SECTOR-SPECIFIC: Healthcare, Medical Research, Public Health. Geographic scope: United States and Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible. Key filtering criteria: Research must focus on long-term post-TB cardiopulmonary sequelae, leverage existing cohorts, and investigate biomarkers and mechanisms of disease. It explicitly excludes studies focused only on pharmacology of TB drugs, multi-drug resistant (MDR) or extensively drug-resistant (XDR) TB, or those with poor adherence to TB therapy. Grant frequency: Recurring with multiple application due dates annually until expiration date.	Funding Up to None USD Deadline May 7, 2026, 10 p.m.	Details

Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)

PAR-25-227

Programme: National Institutes of Health (NIH)

Core objective: Expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs to facilitate appropriate interventions.
Target recipient type and size: A broad range of organizations including Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), Local and Federal Governments, and other entities. There is no specified organizational size limit.
SECTOR-SPECIFIC: This grant is primarily focused on the Healthcare/Medical Research, Public Health, Child Health, Genetics, and Rare Diseases sectors.
Geographic scope: Organizations from the United States and non-U.S. (Foreign Organizations) are eligible to apply.
Key filtering criteria for initial grant screening: Applicants must focus on disorders related to newborn screening and propose research that addresses specific goals such as identifying underlying biological mechanisms, improving diagnostic accuracy, facilitating clinical trials, or establishing data collection systems.
Grant frequency and program context: This is a recurring funding opportunity with multiple application cycles per year until October 2027. It is a reissue of PAR-21-115 and is part of the Hunter Kelly Newborn Screening Research Program within NICHD, aligning with recommendations from the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) and the Recommended Uniform Screening Panel (RUSP).

Funding

Up to None USD

Deadline

Oct. 5, 2027, 5 p.m.

Details

Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)

PAR-25-265

Programme: National Institutes of Health (NIH)

The core objective of this R01 grant is to encourage research that develops novel screening approaches and/or therapeutic interventions for screenable disorders in newborns. This includes conditions already part of newborn screening panels and potentially fatal or disabling genetic conditions that could benefit from early detection. - Target recipients: A wide range of organizations including Higher Education Institutions, Nonprofits, For-Profit Organizations (including Small Businesses), various levels of Government (Local, State, Federal, Tribal), Independent School Districts, Public Housing Authorities, Tribal Organizations, Faith-based/Community-based Organizations, Regional Organizations, and Foreign Organizations. - Organizational size: Not explicitly limited, open to organizations of various capacities capable of conducting research. - Designation: SECTOR-SPECIFIC (Healthcare/Biomedical Research). - Geographic scope: Eligible organizations from the United States and non-U.S. entities (foreign organizations) are welcome to apply. - Key filtering criteria: Projects must focus on research related to newborn screening technologies, assays, or therapeutic interventions for genetic and congenital disorders in infants. - Grant frequency: This is a recurring grant opportunity with multiple application due dates until its expiration in November 2027, reissuing a previous program.

Funding

Up to None USD

Deadline

Nov. 5, 2027, 9 p.m.

Details

Genomic Community Resources (U24 Clinical Trial Not Allowed)

PAR-23-124

Programme: National Institutes of Health (NIH)

Single, clear statement of grant's core objective: To facilitate genomic research by supporting the development and distribution of high-value genomic resources for broad use by the research community.
Explicit identification of target recipient type and size: Open to a wide range of organization types including higher education, non-profits, for-profits (including small businesses), and various government entities.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC
Geographic scope and any location requirements: Global eligibility, open to U.S. and non-U.S. entities (Foreign Institutions).
Key filtering criteria for initial grant screening:
- Project must focus on creating or maintaining broadly applicable genomic resources (e.g., analysis tools, data standards, data production, sample collections).
- Projects supporting only specific diseases or biological questions are not appropriate.
- Clinical trials are not allowed.
- Must demonstrate broad community need and utility.
Grant frequency and program context: Recurring funding opportunity with multiple application due dates until January 2026. Part of the National Institutes of Health (NIH) grant programs, specifically a cooperative agreement (U24) involving substantial federal programmatic involvement.

Funding

Up to None USD

Deadline

Jan. 25, 2026, 10 p.m.

Details

Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)

PAR-25-327

Programme: National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) Ultra-Rare Gene-Based Therapy (URGenT) network

The core objective of this grant is to accelerate the development of gene-based or transcript-directed therapeutic candidates for ultra-rare neurological and neuromuscular disorders. It specifically supports Investigational New Drug (IND)-enabling studies and planning activities for First-in-Human (FIH) clinical testing.

Target Recipient Type: A wide range of organizations including higher education institutions, nonprofits, for-profit organizations (small and large businesses), various government entities, and other specified organizations.
Target Recipient Size: Not explicitly limited by employee count or revenue, open to various organizational sizes with the capacity to conduct complex research.
Designation: SECTOR-SPECIFIC (biomedical research, neuroscience, gene therapy).
Geographic Scope: United States-based organizations. Foreign entities are not eligible to apply, but foreign components within U.S. organizations are allowed.
Key Filtering Criteria:
Focus on ultra-rare neurological and neuromuscular disorders (affecting <= 6,000 people in the U.S.).
Proposed intervention must be a gene-based or transcript-directed therapeutic.
Projects must be ready to undertake IND-enabling studies and clinical trial planning.
Applicants must demonstrate robust proof of concept (POC) data for their therapeutic candidate.
Must have scheduled or held pre-IND discussions with the FDA.
Grant Frequency and Program Context: This is a reissue (PAR-25-327) of a previous funding opportunity (PAR-22-030), indicating a recurring nature. It is part of the National Institute of Neurological Disorders and Stroke (NINDS) Ultra-Rare Gene-based Therapy (URGenT) network.

Funding

Up to None USD

Deadline

Oct. 8, 2027, 5 p.m.

Details

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

PA-20-272

Programme: National Institutes of Health (NIH)

Core objective: Provide administrative supplements to existing NIH research grants and cooperative agreements to cover increased, unforeseen costs within the approved scope.
Target recipient: Program Directors/Principal Investigators (PDs/PIs) holding specific types of NIH research grants.
Size: Not limited by organizational size; applies to various research entities holding NIH grants.
SECTOR-SPECIFIC: Health and Biomedical Research, defined by the missions of participating NIH Institutes/Centers.
Geographic scope: Predominantly United States, implicitly covers institutions eligible for NIH funding.
Key filtering criteria: Applicant must already hold an existing, eligible NIH research grant or cooperative agreement.
Grant frequency: Recurring, as evidenced by its status as a reissue (PA-20-272 reissues PA-18-591), indicating an ongoing program.

Funding

Up to None USD

Deadline

Sept. 30, 2025, midnight

Details

Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)

PAR-25-332

Programme: National Institutes of Health (NIH)

This grant aims to fund research projects focused on current topics in Alzheimer's Disease (AD) and its related dementias (ADRD). It encourages biomedical, social, and behavioral research and training to better understand aging processes and related diseases.

Core Objective: To invite applications for research on current topics in Alzheimer's disease and its related dementias (ADRD).
Target Recipient Type and Size: Open to a wide range of organizations including higher education institutions, nonprofits, for-profit organizations (including small businesses), and various government entities (local, state, federal, tribal). There are no explicit size restrictions, allowing for a broad range of organizational scales.
SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC for health and medical research, particularly neuroscience and aging studies.
Geographic Scope: Worldwide, as non-domestic (non-U.S.) entities are eligible to apply.
Key Filtering Criteria: Focus on AD/ADRD research, organizational type (must be one of the listed categories), and ability to meet extensive federal compliance and reporting requirements.
Grant Frequency and Context: This is a recurring opportunity, a reissue of a previous Notice of Funding Opportunity (NOFO) PAR-22-093, indicating an ongoing commitment to this research area. It is developed in response to recommendations from AD/ADRD Research Summits and the National Alzheimer's Project Act (NAPA).

Funding

Up to None USD

Deadline

Oct. 5, 2027, 10 p.m.

Details

Prospective Research

PRB

Programme: Prospective Research Program

– Core objective: To fund academic research projects that generate new knowledge on societal problems impacting the Brussels-Capital Region, with the goal of informing public policy and political debate by exploring alternatives to existing systems. – Target recipient: Primarily research institutions, including universities, research institutes, and other research-oriented entities. – Type/Size: Targets research institutions of varying sizes, as defined by their primary objective of conducting independent research and disseminating results. – SECTOR-SPECIFIC: This grant is SECTOR-SPECIFIC, focusing on societal challenges, strategic innovation domains, and regional competencies relevant to the Brussels-Capital Region. – Geographic scope: Brussels-Capital Region, Belgium. – Key filtering criteria: Academic research focus, direct relevance to the Brussels-Capital Region's urban challenges, contribution to public policy and debate, and an approach that explores possibilities and alternatives. – Grant frequency and program context: This is a recurring grant program, with a new edition launched annually.

Funding

Up to None EUR

Deadline

Oct. 15, 2025, 9:59 p.m.

Details

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

PAR-25-050

Programme: National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS)

GRANT PURPOSE AND TARGET: - Support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. - Explicit identification of target recipient type and size: The grant targets a wide range of U.S.-based organizations, including higher education institutions, nonprofits, for-profit businesses (small and other), and various government entities. There are no explicit size restrictions, but applicants must have the capacity and expertise for complex research. - SECTOR-SPECIFIC: Healthcare (Neurology, Neuromuscular Disorders) and Technology (Biomarker Analytical Methods). - Geographic scope: Organizations must be based in the United States. Foreign components are allowed within a U.S. application, but foreign entities cannot be the primary applicant. - Key filtering criteria: Focus on analytical validation of biomarkers, not early discovery or clinical efficacy trials. Must address neurological or neuromuscular disorders. Must have preliminary data supporting biomarker utility and a developed detection method. Must specify context(s) of use and include milestones. - Grant frequency and program context: This is a reissue of PAR-24-095, indicating a recurring funding opportunity within the National Institute of Neurological Disorders and Stroke (NINDS) program to advance biomarker development for clinical readiness.

Funding

Up to None USD

Deadline

June 22, 2026, 5 p.m.

Details

Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Training (U2C - Clinical Trial Not Allowed)

PAR-23-248

Programme: National Institutes of Health (NIH)

SECTOR-SPECIFIC: This grant aims to cultivate a highly integrated cohort of pre-doctoral and post-doctoral trainees and early career investigators, and to develop career development resources to accelerate kidney, urologic, and hematologic research.
It targets higher education institutions, nonprofits, and government entities capable of establishing large-scale, interdisciplinary training programs.
Geographic Scope: Primarily US-based institutions. Non-domestic entities are not eligible to apply.
Key filtering criteria: Focus on kidney, urologic, and hematologic research training, cooperative agreement (U2C-TL1) mechanism, clinical trial not allowed for the overall program, but clinical trial experience for trainees is permitted.
Grant Frequency: Recurring, with multiple application due dates until September 2025, reissued from a previous program.

Funding

Up to None USD

Deadline

Sept. 26, 2025, 9 p.m.

Details

Ruth L. Kirschstein National Research Service Award (NRSA) Short-Term Institutional Research Training Grant (Parent T35)

PA-25-280

Programme: Ruth L. Kirschstein National Research Service Award (NRSA)

This grant aims to develop and/or enhance short-term research training opportunities for predoctoral students in biomedical, behavioral, or clinical research.
Target recipients are eligible, domestic institutions, primarily higher education institutions and non-profits, with a focus on supporting health professional students (medical, veterinary, other health-professional programs) and graduate students in physical or quantitative sciences.
This is a SECTOR-SPECIFIC grant, focused on biomedical, behavioral, and clinical research training within health sciences.
Geographic scope is limited to domestic (U.S.) institutions. Foreign organizations or non-U.S. components of U.S. organizations are not eligible.
Key filtering criteria: Applicant must be a U.S. institution with established research training programs capable of supporting predoctoral students for short-term, intensive research experiences (8-12 weeks).
This is a recurring grant opportunity, a reissue of PA-23-080, indicating a continuous program.

Funding

Up to None USD

Deadline

Jan. 25, 2028, 5 p.m.

Details

Kozminski Impact Booster

Programme: Fundusze Europejskie dla Nowoczesnej Gospodarki

This grant aims to provide financial support, mentoring, and technological expert assistance to innovative startups and micro/small enterprises. The core objective is to develop competitive advantages and market maturity, enabling long-term, dynamic growth based on stable market, competence, and capital foundations. - Explicit identification of target recipient type and size: Startups, micro and small enterprises (MŚP). - Primarily SECTOR-SPECIFIC focusing on innovations within National Smart Specializations (such as IT, communication, geoinformation, automation, robotics, sustainable energy), but also includes a SECTOR-AGNOSTIC path for product development. - Geographic scope: Project implementation must be in Poland, with territorial reach extending to Poland and internationally. - Key filtering criteria for initial grant screening: Must be an innovative micro or small enterprise, less than 5 years old from registration, not listed on the stock exchange, and compliant with 'de minimis' aid conditions. - Grant frequency: The accelerator program was planned to execute 5 rounds; however, the current call is stated as 'closed'.

Funding

Up to None PLN

Deadline

June 30, 2026, 11:59 p.m.

Details

NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)

PAR-23-242

Programme: National Institutes of Health (NIH)

This grant, the NCI Research Specialist Award (R50), aims to establish and support stable research career opportunities for exceptional, non-tenure track laboratory-based scientists working within existing NCI-funded cancer research programs. It provides salary and limited travel support to these vital scientists, enabling them to pursue research without sole dependence on grants held by others. - Target Recipient Type: Academic and research institutions applying on behalf of highly skilled, non-tenure track scientists. - Target Recipient Size: SECTOR-AGNOSTIC regarding organizational size, as it supports individuals within various institutional settings (universities, nonprofits, for-profits, government). - Geographic Scope: United States-based organizations; foreign institutions are not eligible. - Key Filtering Criteria: Applicant organization must be US-based; the individual scientist (PD/PI) must be a non-tenure track, lab-based scientist with an advanced degree, significant experience in NCI-funded cancer research, and currently supported by an NCI-funded Unit Director. - Grant Frequency: Recurring, with annual application due dates (November 2023, 2024, 2025).

Funding

Up to None USD

Deadline

Nov. 3, 2025, 5 p.m.

Details

LIFE Programme: EU Funding for Environment and Climate Action

LIFE

Programme: LIFE Programme

To contribute to a better European nature, environment, and climate policy. - Funding for innovative projects that protect the environment, save resources, conserve nature and biodiversity, and raise awareness. - Target recipients: Businesses (SMEs, large enterprises, startups), research institutions, governments, NGOs, and other organizations. - Size: All sizes of organizations. - SECTOR-SPECIFIC: Focuses on environmental, climate, and clean energy sectors. - Geographic Scope: Primarily EU Member States, but activities outside the EU can be funded if they benefit EU environmental/climate goals. - Frequency: Annual calls.

Funding

Up to None EUR

Deadline

Sept. 23, 2025, 10:59 p.m.

Details

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

PAR-24-293

Programme: Blueprint Neurotherapeutics Network

This grant aims to accelerate the discovery and development of diverse biotherapeutic modalities for treating nervous and neuromuscular system disorders. - It supports projects from lead optimization through first-in-human clinical trials. - Target recipients are research teams led by Program Directors/Principal Investigators (PD/PIs) from various eligible organizations. - This grant is SECTOR-SPECIFIC. - Geographic scope includes both domestic (U.S.) and non-domestic (non-U.S.) entities. - Key filtering criteria: focus on biologics, nervous/neuromuscular system disorders, lead optimization to FIH clinical trial stage. - Grant frequency: Recurring, as a re-issue of a previous funding opportunity (PAR-21-163). - Program context: Part of NIH's Blueprint for Neuroscience Research, bridging the gap in biotherapeutics development by providing funding and in-kind resources like Contract Research Organizations (CROs) and consultants.

Funding

Up to None null

Deadline

July 15, 2027, 5 p.m.

Details

Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)

PAR-25-098

Programme: National Institutes of Health (NIH) - ADVANCE Initiative

To test interventions that expand cancer screening and preventive services in NIH-designated health disparity populations by addressing barriers and facilitators at multiple socio-ecological levels. - Explicit identification of target recipient type and size: Primarily research institutions, non-profits, and government entities of various sizes capable of conducting clinical trials. - SECTOR-SPECIFIC - Geographic scope and any location requirements: United States, including U.S. Territories and Possessions. Non-U.S. entities are ineligible. - Key filtering criteria for initial grant screening: Must be a clinical trial, focus on cancer screening/prevention, target health disparity populations, and address multi-level barriers. - Grant frequency and program context: Recurring opportunity (multiple deadlines annually) as part of the NIH's ADVANCE initiative to increase randomized intervention research in health disparities.

Funding

Up to None USD

Deadline

Jan. 7, 2027, 5 p.m.

Details

Translational Neural Devices (R61/R33 - Clinical Trial Optional)

PAR-25-053

Programme: National Institutes of Health (NIH)

Core objective: Advance low-risk therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems by supporting translational activities and small clinical studies.
Explicit identification of target recipient type and size: The grant targets investigators across a broad range of organization types, including academic institutions, non-profits, for-profit businesses (small and large), and various government entities.
SECTOR-SPECIFIC: Healthcare (Medical Devices - Neurology/Neuromuscular).
Geographic scope and any location requirements: Open to organizations within the United States and Non-domestic (non-U.S.) Entities (Foreign Organizations).
Key filtering criteria for initial grant screening: Must focus on low-risk therapeutic or diagnostic neural devices for a single neurological or neuromuscular disorder, follow a two-phase (R61/R33) development model (non-clinical testing leading to a small clinical study), and exclude high-risk clinical trials or basic research.
Grant frequency and program context: This is a recurring funding opportunity, noted as a reissue of PAR-24-151.

Funding

Up to None USD

Deadline

Jan. 28, 2027, 5 p.m.

Details

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)

PA-24-190

Programme: National Institutes of Health (NIH) Research Career Development Program

The core objective of this grant is to attract productive professionals with quantitative science and engineering backgrounds (e.g., mathematics, statistics, computer science, physics) to NIH-relevant biomedical, behavioral, bioimaging, or bioengineering research. It specifically targets individual investigators who propose to serve as the lead researcher for an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial. This is a SECTOR-SPECIFIC grant, focused on health and biomedical research. Geographic scope requires the applicant organization to be U.S.-based. However, foreign components and international sites are permitted for the actual conduct of clinical trials. Key filtering criteria: Individuals must possess an advanced quantitative degree, intend to lead an independent clinical trial, and secure strong institutional and mentorship support within NIH's mission areas. This is a recurring grant opportunity, part of the broader NIH Research Career Development program.

Funding

Up to None USD

Deadline

Feb. 12, 2027, 5 p.m.

Details

Mentored Patient-Oriented Research Career Development Award (Parent K23 – Independent Clinical Trial Not Allowed)

PA-24-185

Programme: NIH Research Career Development Program

The Mentored Patient-Oriented Research Career Development Award (K23) aims to support the career development of individuals with clinical doctoral degrees who are committed to patient-oriented research. It provides salary and research support for 3-5 years of 'protected time' to help these individuals become independent investigators. - Target recipient type: Individuals with clinical doctoral degrees focused on patient-oriented research. - Target recipient size: Individual researchers; associated with organizations of various sizes. - SECTOR-SPECIFIC - Geographic scope: United States organizations only (foreign components of U.S. organizations are allowed, but foreign organizations are not eligible). - Key filtering criteria: Applicant must hold a clinical doctoral degree and commit to patient-oriented research; research must NOT involve leading an independent clinical trial. - Grant frequency: Recurring (Parent NOFO with multiple application due dates until May 2027). - Program context: Part of NIH's broader Research Career Development program to ensure a pool of highly trained scientists in biomedical, behavioral, and clinical research.

Funding

Up to None USD

Deadline

May 8, 2027, 10 p.m.

Details

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

PAR-25-243

Programme: National Institutes of Health (NIH)

This grant aims to support basic, mechanistic research into the biological and genetic causes of cancer health disparities. It seeks to fund innovative studies that investigate these biological/genetic contributors, develop new methodologies and models, and utilize secondary data analyses.

Target recipients: Investigators and scientists with expertise in basic research related to cancer health disparities.
SECTOR-SPECIFIC: Healthcare, specifically cancer research.
Geographic scope: Nationwide (US) and international (Non-U.S. Entities are eligible to apply).
Key filtering criteria: Focus on basic mechanistic research, exclude clinical trials, must address cancer health disparities tied to race/ethnicity.
Grant frequency: Recurring, with multiple application deadlines through October 2027. This is a reissue of a previous funding opportunity (PAR-24-277).

Funding

Up to None USD

Deadline

Nov. 5, 2027, 10 p.m.

Details

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)

PAR-23-148

Programme: National Institutes of Health (NIH) Funding

Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) aims to support epidemiological and observational research on the long-term cardiopulmonary effects after tuberculosis (TB) treatment, particularly focusing on individuals with and without HIV infection.

Primary objective: Characterize and understand adverse outcomes and morbidity associated with post-TB lung disease (PTLD) through additional testing and data collection in existing cohorts.
Target recipients: Researchers and institutions (academic, non-profit, for-profit, government entities).
SECTOR-SPECIFIC: Healthcare, Medical Research, Public Health.
Geographic scope: United States and Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible.
Key filtering criteria: Research must focus on long-term post-TB cardiopulmonary sequelae, leverage existing cohorts, and investigate biomarkers and mechanisms of disease. It explicitly excludes studies focused only on pharmacology of TB drugs, multi-drug resistant (MDR) or extensively drug-resistant (XDR) TB, or those with poor adherence to TB therapy.
Grant frequency: Recurring with multiple application due dates annually until expiration date.

Funding

Up to None USD

Deadline

May 7, 2026, 10 p.m.

Details

You can filter by below criteria

Grants